Saurashtra News

80+ Active Companies working to develop 80+ Pipeline Therapies for Idiopathic Pulmonary Fibrosis Treatment Landscape | Major Companies – Roche, Novartis, Vicore Pharma, and Others.

 Breaking News
  • No posts were found

80+ Active Companies working to develop 80+ Pipeline Therapies for Idiopathic Pulmonary Fibrosis Treatment Landscape | Major Companies – Roche, Novartis, Vicore Pharma, and Others.

April 11
19:52 2023
80+ Active Companies working to develop 80+ Pipeline Therapies for Idiopathic Pulmonary Fibrosis Treatment Landscape | Major Companies - Roche, Novartis, Vicore Pharma, and Others.

DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Idiopathic Pulmonary Fibrosis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Idiopathic Pulmonary Fibrosis NDA approvals (if any), and product development activities comprising the technology, Idiopathic Pulmonary Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Insight Report

 

  • DelveInsight’s analysis presents Idiopathic Pulmonary Fibrosis Pipeline with 80+ active players in the domain investigating 80+ pipeline therapies.

 

  • The leading Idiopathic Pulmonary Fibrosis Companies include Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche,  Kinarus,  Insmed, Avalyn Pharmaceuticals,  Bridge Biotherapeutics, and others.

 

  • Promising Idiopathic Pulmonary Fibrosis pipeline therapies include DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitil, AP01, BBT-877, and others

 

  • The Idiopathic Pulmonary Fibrosis Companies and academics are working to assess challenges and seek opportunities that could influence Idiopathic Pulmonary Fibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Idiopathic Pulmonary Fibrosis. 

 

To explore more information on the latest breakthroughs in the Idiopathic Pulmonary Fibrosis Pipeline treatment landscape of the report, click here @ Idiopathic Pulmonary Fibrosis Pipeline Outlook

 

Idiopathic Pulmonary Fibrosis Overview

Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time.

 

Recent Breakthroughs of Idiopathic Pulmonary Fibrosis Treatment Landscape

 

  • In February 2022, Endeavor BioMedicines, announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners. New investors participating in the round include Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, funds managed by Tekla Capital Management LLC, and funds and accounts advised by T. Rowe Price Associates, Inc. Existing investors Omega Funds and Longitude Capital also participated. Proceeds will support the advancement of Endeavor’s pipeline programs, including ENV-101 (taladegib), a small molecule inhibitor of the PTCH1 receptor in the Hedgehog signaling pathway for the treatment of cancer and idiopathic pulmonary fibrosis (IPF), as well as ENV-201, a potentially best-in-class small molecule inhibitor of ULK1/2 for the treatment of KRAS-driven cancers.

 

  • In October 2021, Agomab Therapeutics NV entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders.

 

  • In September 2021, Syndax Pharmaceuticals, Inc. and Incyte entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax’s anti-CSF-1R monoclonal antibody. Syndax and Incyte are seeking to develop axatilimab as a backbone therapy for patients with cGVHD as well as in additional immune-mediated diseases where CSF-1R-dependent monocytes and macrophages are believed to contribute to organ fibrosis.

 

  • In April 2021, Syndax Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatilimab, its anti-CSF-1R monoclonal antibody, for the treatment of patients with idiopathic pulmonary fibrosis (IPF). 

 

For further information, refer to the detailed Idiopathic Pulmonary Fibrosis Unmet Needs, Idiopathic Pulmonary Fibrosis Market Drivers, and Idiopathic Pulmonary Fibrosis Market Barriers, click here for Idiopathic Pulmonary Fibrosis Ongoing Clinical Trial Analysis

 

Idiopathic Pulmonary Fibrosis Emerging Drugs Profile

 

PRM-151: Hoffmann-La Roche

PRM-151 is an anti-fibrotic immunomodulator being developed for treatment of fibrotic diseases. It is a recombinant form of human pentraxin-2 (PTX-2) protein, presents new opportunities for treating a wide range of systemic fibrotic diseases. Currently, it is in Phase III stage of development to treat Idiopathic pulmonary fibrosis. Pentraxin-2 is an endogenous human protein that plays an important role in regulating the response to fibrosis. It directs the immune system to naturally turn off and reverse the process of fibrosis, which occurs as a result of excess collagen secretion and cellular growth and differentiation. Unlike other formulations that work by stopping a single target on the downstream side of fibrosis, this protein works by reversing and possibly healing the fibrotic tissue. Research suggests that it may localize specifically to sites of injury and function to aid in the removal of damaged tissue. Combined with the ability to regulate monocyte differentiation (another inflammatory regulator), it has been proven to have ‘first-class’ effects in reversal of fibrosis and promotion of healing.

 

Pamrevlumab: FibroGen

Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and for the treatment of Duchenne muscular dystrophy (DMD). The U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to pamrevlumab for the treatment of patients with IPF, LAPC, and DMD. Pamrevlumab has also received Fast Track designation from the U.S. Food and Drug Administration for the treatment of patients with IPF and LAPC. Across all clinical studies, pamrevlumab has consistently demonstrated a good safety and tolerability profile to date.

 

Tipelukast: MediciNova

MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development and MN-001’s inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models. Previously, MediciNova evaluated MN-001 for its potential clinical efficacy in asthma and had positive Phase 2 results. MN-001 has been exposed to more than 600 subjects and considered generally safe and well-tolerated.

 

PLN-74809: Pliant Therapeutics

PLN-74809 is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). While expressed at very low levels in normal tissues, αvβ6 and αvβ1 integrins are upregulated in the pulmonary tissues of IPF patients, and in the liver tissues of PSC patients. Both of these integrins serve as activators of TGF-ß, leading to increased collagen production and, ultimately, fibrosis in these tissues. By blocking the activation of TGF-ß by both αvβ6 and αvβ1, we believe PLN-74809 may slow and potentially halt the progression of fibrosis in these patient populations. In November 2018, the US FDA granted orphan drug designation for PLN 74809 for the treatment of primary sclerosing cholangitis. Earlier, in August 2018, the drug received orphan drug designation for the treatment of idiopathic pulmonary fibrosis.

 

GLPG4716: Galapagos NV

GLPG4716 (formerly OATD-01, in-licensed from OncoArendi) is a novel, small molecule CHIT1/AMCase inhibitor targeting a key pathway in tissue remodeling. It has shown compelling translational data, a favorable profile in animal studies at expected therapeutic doses and it has successfully completed Phase I studies in healthy volunteers. Galapagos aims to bring GLPG4716 to a Phase II clinical trial for the treatment of IPF and possibly other diseases with a fibrotic component. Chitinases (predominantly CHIT1) are involved in macrophage activation. Inhibition of chitinase activity translates into a potential therapeutic benefit, as shown in a range of preclinical models. GLPG4716 has shown robust anti-fibrotic activity in multiple animal models, when compared with the standard of care.

 

Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Idiopathic Pulmonary Fibrosis. The companies which have their Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage, i.e. phase III include, Hoffmann-La Roche.

 

Request a sample and discover the recent advances in Idiopathic Pulmonary Fibrosis Ongoing Clinical Trial Analysis and Medications, click here @ Idiopathic Pulmonary Fibrosis Treatment Landscape

 

Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report

 

  • Coverage- Global

 

  • Idiopathic Pulmonary Fibrosis Companies- Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche,  Kinarus,  Insmed, Avalyn Pharmaceuticals,  Bridge Biotherapeutics, and others

 

  • Idiopathic Pulmonary Fibrosis Pipeline Therapies- DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitic, AP01, BBT-877, and others

 

  • Idiopathic Pulmonary Fibrosis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Idiopathic Pulmonary Fibrosis Market Drivers and Idiopathic Pulmonary Fibrosis Market Barriers, click here @ Idiopathic Pulmonary Fibrosis Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Idiopathic Pulmonary Fibrosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Idiopathic Pulmonary Fibrosis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. PRM-151: Hoffmann-La Roche
  9. Mid Stage Products (Phase II)
  10. Tipelukast: MediciNova
  11. Early Stage Products (Phase I/II)
  12. Lung stem cells: Regend Therapeutics
  13. Early Stage Products (Phase I)
  14. LTI-03: Lung Therapeutics
  15. Preclinical and Discovery Stage Products
  16. AD-214: Adalta
  17. Inactive Products
  18. Idiopathic Pulmonary Fibrosis Key Companies
  19. Idiopathic Pulmonary Fibrosis Key Products
  20. Idiopathic Pulmonary Fibrosis- Unmet Needs
  21. Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
  22. Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
  23. Idiopathic Pulmonary Fibrosis Analyst Views
  24. Idiopathic Pulmonary Fibrosis Key Companies
  25. Appendix

 

Got Queries? Find out the related information on Idiopathic Pulmonary Fibrosis Mergers and acquisitions, Idiopathic Pulmonary Fibrosis Licensing Activities @ Idiopathic Pulmonary Fibrosis Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/